Marksans Pharma Limited has informed the Exchange regarding a press release dated October 15, 2025, titled "Marksans Pharma Ltd's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its products from UK MHRA".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly owned UK-based subsidiary Relonchem Limited has received Marketing Authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its products. This regulatory approval allows Relonchem to market and sell these products in the UK market. The approval strengthens Marksans Pharma's presence in the UK pharmaceutical market through its subsidiary. This comes as part of the company's ongoing strategy to expand its regulated market footprint.
Positive for shareholders as the UK MHRA approval enables product commercialisation in a key regulated market, potentially adding to the company's UK revenue stream from its subsidiary.